Failure of resolution of portal fibrosis during omega-3 fatty acid lipid emulsion therapy in two patients with irreversible intestinal failure

J Pediatr. 2010 Feb;156(2):327-31. doi: 10.1016/j.jpeds.2009.08.033.

Abstract

Parenteral omega-3 fatty acid lipid emulsions have been evaluated for their potential role in reversing intestinal failure-associated liver disease. We report our experience using Omegaven in 2 patients with irreversible intestinal failure and intestinal failure-associated liver disease. Despite biochemical and histologic improvement in cholestasis, both patients had persisting, significant portal fibrosis on liver biopsy.

Publication types

  • Case Reports

MeSH terms

  • Fat Emulsions, Intravenous / therapeutic use*
  • Fatty Acids, Omega-3 / therapeutic use*
  • Female
  • Hirschsprung Disease / therapy*
  • Humans
  • Infant, Newborn
  • Intestinal Diseases / therapy*
  • Liver Cirrhosis, Biliary / pathology
  • Liver Cirrhosis, Biliary / therapy*
  • Male
  • Parenteral Nutrition / adverse effects
  • Parenteral Nutrition / methods*
  • Treatment Failure

Substances

  • Fat Emulsions, Intravenous
  • Fatty Acids, Omega-3